• Life Advice & Visual Arts Welcome Guest
    Posting Rules Bluelight Rules
    🌌 Share Your Dreams! 🌌
    📸 15 Years of Photo Contests 📸
  • LAVA Moderator: streaM Freak

the market: stocks, bonds, options, whatever

rate cut odds jump again

sudden inflows into crypto

i broke my no monday trading rule and got reminded why i had that rule in the forst place -_-
 
the instability is very noticeable in the markets. Except for gold and silver which silver keeps going up.
Bitcoin would dive from 91-85 ever couple of days and it did this at least twice in the past week.
 
still kicking myself over getting out of GOOG, it hit the analysts price target quick

i'm long MU again because of RAM supply shortages but the upside from that could already be priced in

shoulda loaded up on SOXL during the last dip...

shit's not going my way so far this month.

hail mary play is fed saying no cut
 
i wouldn't mess with XAG right now either, i mean come on that's just a crazy price

hmm.. actually, might be good to try shorting that at $60
 
CAPR could be legit now. Gotta let the stock settle down, and hope their NDA gets approved after the new phase 3 data, and if approved then hope their drug rollout is done well and has demand

  • Complete Response Letter (CRL): In July 2025, the FDA issued a CRL, declining to approve the application in its current form due to a lack of substantial evidence of effectiveness and the need for additional clinical data. The review had advanced without major issues up to that point, including a successful manufacturing inspection.
  • New Data and Resubmission Plan: Capricor engaged with the FDA post-CRL and planned to use data from its ongoing Phase 3 HOPE-3 clinical trial to address the FDA's concerns.
  • Positive Phase 3 Results: On December 3, 2025, Capricor announced positive topline results from the pivotal Phase 3 HOPE-3 study, which met its primary endpoint by showing a slower decline in upper limb function in patients treated with deramiocel compared to a placebo.
  • Current Status: The company plans to use these new results in its resubmission to the FDA. The FDA has indicated this would be a Class 2 resubmission, which typically has a six-month review timeline.
Click to expand...
 
apparently shkreli got liquidated shorting CAPR. fucking small caps are such bullshit

MU rising again

NVDA and AMD ripped higher in postmarket on approval to sell chips in China

not clear yet if Beijing is planning to lift their own ban...

meanwhile TSLA dumped, I was eyeing the 405 range before but was all tied up when it dropped

this time I'm eyeing 420, if it drops lower then there might be a good chance to short on the retest
 
baby-chart-finance-rollercoaster-amateur-freakingout.gif
 
hmm i'm not that confident about shorting silver

MSTR is in the maybe box though
 
It's had a lot of reverse splits because it's a bear etf so it was actually like $10/share back then
 
You must log in or register to reply here.
Top